World-First Clinical Trial, Refractory Epilepsy

Flowonix® Medical Inc. and Cerebral Therapeutics Announce World-First Clinical Trial Delivering Medication Directly into the Brain for Patients with Refractory Epilepsy

Authors:
Flowonix Medical Inc.
Date:
PRNewswire: March 14, 2017 – MOUNT OLIVE, NJ, U.S.A. – Flowonix Medical Inc. of New Jersey and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra® II programmable infusion system in the Australian Direct Drug Administration for Refractory Epilepsy (…

join_crs.jpg